Towards improved diagnosis of von Willebrand disease: Comparative evaluations of several automated von Willebrand factor antigen and activity assays

Thrombosis Research

Volumn 134, Issue 6, 2014, Pages 1292-1300

  Favaloro, Emmanuel J ^a   Mohammed, Soma ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Collagen binding; INNOVANCE VWF activity; Laboratory testing; Ristocetin cofactor; von Willebrand disease; von Willebrand factor

Indexed keywords

COLLAGEN; DESMOPRESSIN; GLYCOPROTEIN IB; HETEROPHILE ANTIBODY; LATEX; POLYCLONAL ANTIBODY; RISTOCETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND ANTIGEN;

ANALYZER; ARTICLE; ASSAY; BLEEDING DISORDER; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; LABORATORY TEST; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; VON WILLEBRAND DISEASE; BLOOD; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; EVALUATION STUDY; IMMUNOASSAY; IMMUNOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASES;

DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; IMMUNOASSAY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84915821040     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.09.024     Document Type: Article

References (43)

1. E.J. Favaloro Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder Semin Thromb Hemost 37 2011 440 455
2. V.H. Flood Perils, problems, and progress in laboratory diagnosis of von Willebrand disease Semin Thromb Hemost 40 2014 41 48
3. A. Yee, and C.A. Kretz von Willebrand Factor: Form for Function Semin Thromb Hemost 40 2014 17 27
4. E.J. Favaloro Rethinking the diagnosis of von Willebrand disease Thromb Res 127 Suppl. 2 2011 s17 s21
5. E.J. Favaloro, R.A. Bonar, M. Meiring, E. Duncan, S. Mohammed, and J. Sioufi Evaluating errors in the laboratory identification of von Willebrand disease in the real world Thromb Res 134 2014 393 403
6. E.J. Favaloro, I. Bodó, S.J. Israels, and S.A. Brown von Willebrand disease and platelet disorders Haemophilia 20 Suppl. 4 2014 59 64
7. E.J. Favaloro Diagnosing von Willebrand Disease: A Short History of Laboratory Milestones and Innovations, Plus Current Status, Challenges, and Solutions Semin Thromb Hemost 40 2014 551 570
8. J.E. Sadler, U. Budde, J.C. Eikenboom, E.J. Favaloro, F.G. Hill, and L. Holmberg Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor J Thromb Haemost 4 2006 2103 2114
9. W.L. Nichols, M.B. Hultin, A.H. James, M.J. Manco-Johnson, R.R. Montgomery, and T.L. Ortel Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA) Haemophilia 14 2008 171 232
10. E.J. Favaloro, M. Franchini, and G. Lippi Biological therapies for von Willebrand Disease Expert Opin Biol Ther 12 2012 551 564
11. E.J. Favaloro, M. Plebani, and G. Lippi Regulation in hemostasis and thrombosis: Part I-in vitro diagnostics Semin Thromb Hemost 39 2013 235 249
12. D.M. Adcock, M. Bethel, and A. Valcour Diagnosing von Willebrand disease: a large reference laboratory's perspective Semin Thromb Hemost 32 2006 472 479
13. V.H. Flood, J.C. Gill, K.D. Friedman, P.A. Christopherson, P.M. Jacobi, and R.G. Hoffmann Collagen binding provides a sensitive screen for variant von Willebrand disease Clin Chem 59 2013 684 691
14. U. Budde, A. Pieconka, K. Will, and R. Schneppenheim Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification Semin Thromb Hemost 32 2006 514 521
15. E.J. Favaloro, L. Grispo, T. Exner, and J. Koutts Development of a simple collagen binding assay aids in the diagnosis of, and permits sensitive discrimination between, Type I and Type II von Willebrand's disease Blood Coagul Fibrinolysis 2 1991 285 291
16. E.J. Favaloro Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease Thromb Haemost 104 2010 1009 1021
17. E.J. Favaloro, S. Mohammed, and J. McDonald Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay J Thromb Haemost 8 2010 2842 2844
18. E.J. Favaloro, L. Grispo, T. Exner, and J. Koutts Development of a simple collagen binding assay aids in the diagnosis of, and permits sensitive discrimination between, Type I and Type II von Willebrand's disease Blood Coagul Fibrinolysis 2 1991 285 291
19. E.J. Favaloro, L. Grispo, A. Dinale, M. Berndt, and J. Koutts von Willebrand's Disease: Laboratory investigation using an improved functional assay for von Willebrand Factor Pathology 25 1993 152 158
20. E.J. Favaloro, D. Facey, and L. Grispo Laboratory assessment of von Willebrand Factor: Use of different assays can influence the diagnosis of von Willebrand's Disease, depending on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms Am J Clin Pathol 104 1995 264 271
21. E.J. Favaloro, and J. Koutts Laboratory assays for von Willebrand Factor: Relative contribution to the diagnosis of von Willebrand's disease Pathology 29 1997 385 391
22. E.J. Favaloro Collagen binding assay for von Willebrand Factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source Thromb Haemost 83 2000 127 135
23. E.J. Favaloro, A. Henniker, D. Facey, and M. Hertzberg Discrimination of von Willebrands Disease (VWD) subtypes: Direct comparison of von Willebrand Factor:Collagen binding activity/assay (VWF:CBA) with Monoclonal Antibody (MAB) based ELISA VWF-detection systems Thromb Haemost 84 2000 541 547
24. E.J. Favaloro Detection of von Willebrand Disorder (VWD) and identification of qualitative von Willebrand Factor (VWF) defects: Direct comparison of commercial ELISA-based 'VWF:Activity' options Am J Clin Pathol 114 2000 608 618
25. E.J. Favaloro, M. Krigstein, J. Koutts, T. Brighton, and R. Lindeman Genetic testing for the diagnosis of von Willebrand Disease: benefits and limitations J Coagul Disord 2 2010 37 47
26. E.J. Favaloro, M. Dean, L. Grispo, T. Exner, and J. Koutts von Willebrand's Disease: Use of Collagen Binding Assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy Am J Hematol 45 1994 205 211
27. E.J. Favaloro, J. Thom, D. Patterson, S. Just, T. Dixon, and J. Koutts Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 123 2009 862 868
28. E.J. Favaloro Diagnosis of type 1 versus 2A and 2M von Willebrand disease Haemophilia 18 2012 e9 e11
29. E.J. Favaloro, C. Forsyth, and J. Koutts Distinguishing types 1 and 2 M von Willebrand disease Int J Lab Hematol 34 2012 102 105
30. E.J. Favaloro, R. Bonar, K. Chapman, M. Meiring, and D.F. Adcock Differential sensitivity of von Willebrand factor 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody based assays J Thromb Haemost 10 2012 1043 1054
31. E.J. Favaloro, M. Aboud, and C. Arthur Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor Am J Hematol 66 2001 53 56
32. G. Lippi, L. Ippolito, M.T. Tondelli, and E.J. Favaloro Interference from heterophilic antibodies in D-dimer assessment. A case report Blood Coagul Fibrinolysis 25 2014 277 279
33. F. Ratzinger, K.G. Schmetterer, H. Haslacher, T. Perkmann, S. Belik, and P. Quehenberger Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories Clin Chem Lab Med 52 2014 1193 1202
34. A.S. Lawrie, S. Kitchen, M. Efthymiou, I.J. Mackie, and S.J. Machin Determination of APTT factor sensitivity-the misguiding guideline Int J Lab Hematol 35 2013 652 657
35. L.T. Sharief, A.S. Lawrie, I.J. Mackie, C. Smith, F. Peyvandi, and R.A. Kadir Changes in factor XIII level during pregnancy Haemophilia 20 2014 e144 e148
36. A.S. Lawrie, F. Stufano, M.T. Canciani, I.J. Mackie, S.J. Machin, and F. Peyvandi A comparative evaluation of a new automated assay for von Willebrand factor activity Haemophilia 19 2013 338 342
37. L. Graf, K.A. Moffat, S.A. Carlino, A.K. Chan, A. Iorio, and A. Giulivi Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin Int J Lab Hematol 36 2014 341 351
38. U. Geisen, B. Zieger, L. Nakamura, A. Weis, J. Heinz, and J.J. Michiels Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo Thromb Res 134 2014 246 250
39. R. Schneppenheim, T. Obser, U. Budde, and J. Patzke Development of a new functional assay for von Willebrand factor binding to platelet GPIba that does not require ristocetin Hamostaseologie 30 2010 A28 [Abstract FC4-05 of the 54th Annual Meeting of the GTH]
40. J. Patzke, H. Muth, M. Wilkens, H. Althaus, U. Budde, and R. Schneppenheim Development of a gain-of-function GPIBA binding assay as an alternative to the ristocetin cofactor assay (7th Bari International Conference; Abstract PO004) Blood Transfus 9 S 3 2011 s7
41. A.R. Huber, U. Budde, J. Patzke, and H. Muth Comparative evaluation of a new von Willebrand factor activity assay J Thromb Haemost 9 2011 919 [Abstract P-TH-479 of the XXII ISTH Congress]
42. U. Budde, R. Schneppenheim, A. Mendez, J. Patzke, and H. Muth Clinical evaluation of a new von Willebrand Factor activity assay J Thromb Haemost 9 2011 913 [Abstract P-TH-461 of the XXII ISTH Congress]
43. J. Patzke, H. Muth, M. Wilkens, and R. Schneppenheim Performance data of the new automated von Willebrand factor activity assay based on GPIbα binding Hamostaseologie 2011 [Abstract No. P-12-5 of the 54th Annual Meeting of the GTH]